CDRI-93/478 is a potent anti-ischemic and anti-hypertensive agent. This com
pound is in advanced stage of pre-clinical trials. A high-performance liqui
d chromatographic (HPLC) method was developed for the analysis of CDRI-93/4
78 in rat serum. a species used for safety evaluation, The HPLC analysis, a
pplicable to I ml volumes of serum, involved double extraction of serum sam
ples with diethyl ether at alkaline pH followed by separation on a spheri-5
cyano column and the use of fluorescence detector at excitation wavelength
250 nm and emission wavelength 372 nm. The method was sensitive with a lim
it of quantitation of 10 ng ml(-1) in rat serum and the recovery was more t
han 84%. The linearity was satisfactory as indicated by correlation of >0.9
9, in addition to the visual examination of the calibration curves. The pre
cision and accuracy were acceptable as indicated by relative standard devia
tion (R.S.D.) ranging from 1.73 to 9.51%, bias values ranging from -7.31 to
8.68%. Moreover. CDRI-93/478 was stable in rat serum after being subjected
to three freeze-thaw cycles. In-process stability evaluation showed the st
ability of the compound in processed samples lasted up to 168 h. The assay
was found to be sensitive, specific, accurate, precise, and reliable for us
e in pharmacokinetic or toxicokinetic studies. (C) 2001 Elsevier Science B.
V. All rights reserved.